Beyond canonical fusion-driven settings, preclinical work indicates that NGF–TrkA signaling can be pharmacologically suppressed to blunt prometastatic programmes even in fusion-negative osteosarcoma. The gene discussed is NGF; the disease is osteosarcoma.